NetworkNewsBreaks – Genprex Inc.’s (NASDAQ: GN
Post# of 231
(Total Views: 215)
Posted On: 07/06/2023 4:10:29 PM
NetworkNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Unique Treatment Paradigm Featured in Bell2Bell Podcast
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, was featured in the latest episode of Bell2Bell Podcast. The podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Rodney Varner, GNPX’s chairman, president and CEO, and Ryan Confer, the company’s CFO, joined the program to discuss the journeys that led them to Genprex and the promise of the company’s drug development pipeline. “As I learned more and more about the technology, it became a passion of mine, as well,” said Confer. “What we’re trying to do in cancer – using a lipid-based delivery vehicle and working with tumor suppressor genes that are naturally occurring in the body – represents a treatment paradigm that is unique and different than other options in the space, particularly chemotherapy that has such negative side effects. It is something that we believe really has the potential to change people’s lives as they’re going through such a terrible prognosis. I was excited then, and here we are 12 years later, being able to see it coming through clinical trials, seeing how safe the program has been and seeing the impact that we’re having.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, was featured in the latest episode of Bell2Bell Podcast. The podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Rodney Varner, GNPX’s chairman, president and CEO, and Ryan Confer, the company’s CFO, joined the program to discuss the journeys that led them to Genprex and the promise of the company’s drug development pipeline. “As I learned more and more about the technology, it became a passion of mine, as well,” said Confer. “What we’re trying to do in cancer – using a lipid-based delivery vehicle and working with tumor suppressor genes that are naturally occurring in the body – represents a treatment paradigm that is unique and different than other options in the space, particularly chemotherapy that has such negative side effects. It is something that we believe really has the potential to change people’s lives as they’re going through such a terrible prognosis. I was excited then, and here we are 12 years later, being able to see it coming through clinical trials, seeing how safe the program has been and seeing the impact that we’re having.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)